Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ankylosing Spondylitis Patients Taking COX-2 Inhibitors May See Fewer CV Events

Key clinical point: Individuals with ankylosing spondylitis (AS) who took cyclooxygenase 2 (COX-2) inhibitors had a reduced risk of cardiovascular events, compared with AS patients who were not using COX-2 inhibitors.

Major finding: Individuals with AS taking COX-2 inhibitors had a risk ratio of 0.48 for cardiovascular events (95% CI, 0.33-0.70; P = .001).

Study details: Systematic review and meta-analysis of nine observational studies that variably examined the association between NSAID use and tumor necrosis factor inhibitor use and cardiovascular events among individuals with AS.

Disclosures: The authors reported no conflicts of interest and no outside sources of funding.

Citation:

Karmacharya P. et al. SPARTAN 2019.